BixiBat: Safe Relief for Chronic Constipation in Cardiac Patients, Chronic constipation, Elobixibat, General Practitioner, Consultant Physician, General Practice, Constipation Management, Gastroenterology, Gastroenterologist, Consultant Physician, SBM: Spontaneous Bowel Movement, CSBM: Complete Spontaneous Bowel Movement
This article is brought to you by Bixibat
This Article is brought to you by BixiBat
Elobixibat Is Safe and Effective to Use in Patients With
Heart Failure/Cardiac Disorders and Chronic Constipation
 |
An open-label, single-center, single-arm, controlled before-and-after prospective study to evaluate the efficacy and safety of elobixibat in HF patients with chronic constipation |
 |
18 patients (≥20 years old) with chronic constipation (Rome IV) and HF (NYHA Class II–III) |
 |
Elobixibat 10 mg/day |
The degree of straining during defecation significantly ↓ at all time points.
 |
3 patients experienced AEs (17%). |
No serious AEs occurred during the study period. |
2 patients experienced diarrhea (11%). |
*p<0.05, **p<0.01. #As assedded by JPAC-QOL score
 |
ConclusionElobixibat could be safely administered to treat chronic constipation in HF patients. |
#For all variables (SBP, DBP, and mean BP) at week 12 from baseline.
AE: Adverse event; BP: Blood pressure; BSFS: Bristol Stool Form Scale; DBP: Diastolic blood pressure; HF: Heart failure; NYHA: New York Heart Association; SBM: Spontaneous bowel movement; SBP: Systolic blood pressure.
Reference: Fujisue K, Ito M, Matsuzawa Y, et al. Open-label, single-center, single-arm study evaluating the efficacy and safety of elobixibat for chronic constipation in patients with heart failure. Circ Rep. 2024;6(3):55–63.
For the use of a Registered Medical Practitioner, Hospital or a Laboratory only. GGI-CO-A1-AQS-300041570-ELC-L24-0760
